Adial Pharmaceuticals, Inc. has announced a collaboration with Boudicca Dx, LLC to advance its technical and regulatory strategy for the companion diagnostic genetic test for AD04, a genetically targeted, serotonin-3 receptor antagonist therapeutic agent for the treatment of Alcohol Use Disorder (AUD). Boudicca will support Adial in ensuring that the diagnostic test is validated both technically and clinically per FDA guidelines.
Company Information
Company
Adial Pharmaceuticals
Location
Glen Allen, Virginia, United States
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARDTM pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Glen AllenBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical